Syntis Bio received a $33 million to advance its oral therapy platform for obesity, diabetes, and rare metabolic diseases. The company’s nutrient-blocking pill leverages transient polymer coatings and gut-stable enzyme therapies to provide a non-surgical treatment option that mimics the benefits of bariatric surgery while expanding therapeutic possibilities for rare metabolic disorders.
